Response Biomedical's Q2 Revenues Slide 18 Percent

While product revenues improved, driven by double-digit growth in clinical products, the company took a 79 percent hit in its contract service fees and revenues from collaborative research arrangements.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories